Gut microbiota linked to sexual preference and HIV infection M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... EBioMedicine 5, 135-146, 2016 | 402 | 2016 |
Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 25 (3), 221-228, 2000 | 345 | 2000 |
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ... Aids 14 (4), 397-403, 2000 | 259 | 2000 |
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and … E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, ... Clinical infectious diseases 34 (4), 504-510, 2002 | 234 | 2002 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study A Bonjoch, M Figueras, C Estany, N Perez-Alvarez, J Rosales, L del Rio, ... Aids 24 (18), 2827-2833, 2010 | 216 | 2010 |
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a … L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 27 (3), 229-236, 2001 | 214 | 2001 |
HIV and syphilis: when to perform a lumbar puncture AÈ Libois, SÉ De Wit, BÉÉ Poll, F Garcia, E Florence, A Del Rio, ... Sexually transmitted diseases 34 (3), 141-144, 2007 | 209 | 2007 |
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence CR Fumaz, JA Munoz-Moreno, J Moltó, E Negredo, MJ Ferrer, G Sirera, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 38 (5), 560-565, 2005 | 209 | 2005 |
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens CR Fumaz, A Tuldra, MJ Ferrer, R Paredes, A Bonjoch, T Jou, E Negredo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 29 (3), 244-253, 2002 | 202 | 2002 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 169 | 2018 |
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients … E Negredo, M Massanella, J Puig, N Pérez-Alvarez, JM Gallego-Escuredo, ... Clinical infectious diseases 50 (9), 1300-1308, 2010 | 169 | 2010 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ... HIV medicine 21 (10), 617-624, 2020 | 167 | 2020 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials SK Gupta, FA Post, JR Arribas, JJ Eron Jr, DA Wohl, AE Clarke, PE Sax, ... Aids 33 (9), 1455-1465, 2019 | 160 | 2019 |
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load E Negredo, J Moltó, D Burger, P Viciana, E Ribera, R Paredes, M Juan, ... Aids 18 (3), 459-463, 2004 | 152 | 2004 |
CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART M Massanella, E Negredo, N Pérez-Álvarez, J Puig, R Ruiz-Hernández, ... Aids 24 (7), 959-968, 2010 | 151 | 2010 |
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients JA Muñoz-Moreno, CR Fumaz, MJ Ferrer, A Prats, E Negredo, M Garolera, ... AIDS research and human retroviruses 24 (10), 1301-1307, 2008 | 142 | 2008 |
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis S Mathis, B Khanlari, F Pulido, M Schechter, E Negredo, M Nelson, ... PloS one 6 (7), e22003, 2011 | 140 | 2011 |
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine E Negredo, J Ribalta, R Paredes, R Ferré, G Sirera, L Ruiz, J Salazar, ... Aids 16 (10), 1383-1389, 2002 | 138 | 2002 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine A Barrios, A Rendón, E Negredo, P Barreiro, T Garcia-Benayas, ... Aids 19 (6), 569-575, 2005 | 136 | 2005 |
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial JR Santos, M Saumoy, A Curran, I Bravo, JM Llibre, J Navarro, C Estany, ... Clinical Infectious Diseases 61 (3), 403-408, 2015 | 128 | 2015 |